What is "amibegron"

n. A drug that acts as a selective agonist for the β₃ adrenergic receptor, with antidepressant and anxiolytic effects.

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β adrenergic receptor. It is the first orally active β agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.